Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
May 4, 2009
- Shionogi Expands Support Systems for Female MRs
May 4, 2009
- Pharmacists Should Be Encouraged to Dispense More Generics
May 4, 2009
- GSK to Lead Respiratory Drug Market with Adoair
May 4, 2009
- JSHP to More Actively Cooperate with the Use of More Generics
May 4, 2009
- Toyota Tsusho to Represent ChemRoutes in Japan
May 4, 2009
- Patient Education Important to Promote Use of Generics
May 4, 2009
- BUSINESS NEWS IN BRIEF
May 4, 2009
- SSP Aims at ¥2 Bil. with Switch OTC Version of Diclofenac
May 4, 2009
- PhRMA to Support NHI Price Maintenance System: Mr Sekiguchi
May 4, 2009
- Magnesium Oxide Should Remain Class 3 OTC Drug: Society
May 4, 2009
- Korosho to Speed Up Development of Anticancer, Pediatric Drugs Using Supplementary Budget
May 4, 2009
- Focusing on the Task at Hand
May 4, 2009
- More Companies Show Interest in Collaborative Multinational Trials: Mr Nakagaki
May 4, 2009
- Taisho: Switch OTC Drug Containing Tiquizium Bromide
May 4, 2009
- NBI's Telmisartan + HCT Combinations Approved
May 4, 2009
- Bonoteo Prevents Fractures in Severe Osteoporosis Patients
May 4, 2009
- REGULATORY NEWS IN BRIEF
May 4, 2009
- Explanation of Steroids Required to Overcome Patient's Anxieties
May 4, 2009
- Working Hours of Obstetricians Longest in Japan
May 4, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…